Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental approval for labeling changes to levetiracetam extended-release formulations; does not report clinical trial outcomes or comparative efficacy.
FDA supplemental approval of labeling for valproic acid syrup; this is a regulatory action record, not a clinical study, and does not contain efficacy or safety trial data.